Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;182(21):5355-5377.
doi: 10.1111/bph.70118. Epub 2025 Jul 11.

Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

Océane Pointeau  1 , Awa Isma Ba  1 , Audrey Geissler  1   2 , Romain Barbosa  1 , Abhishek Basu  3 , Arif Muhammad  3   4 , Marina Nivot  1 , Maéva Loriot  1 , Julia Leemput  1 , Patricia Passilly-Degrace  1 , Sébastien Causse  1 , Laurent Demizieux  1 , Hélène François  5   6 , Bruno Vergès  1 , Jianmin Duan  7 , Geneviève Gaucher  7 , Michael Harvey  7 , Pascal Degrace  1 , Glenn Crater  7 , Resat Cinar  3 , Tony Jourdan  1
Affiliations

Blockade of cannabinoid CB1 receptors potentiates the anti-fibrotic effects mediated by SGLT2 inhibition in a mouse model of diabetic nephropathy

Océane Pointeau et al. Br J Pharmacol. 2025 Nov.

Abstract

Background and purpose: Diabetic nephropathy (DN) is a common complication of diabetes. Current treatments include renin-angiotensin-aldosterone system (RAAS) blockers and sodium-glucose co-transporter 2 (SGLT2) inhibitors. The cannabinoid CB1 receptor is a potential therapeutic target. We explored combining CB1 receptor inverse agonism and SGLT2 inhibition for treating DN, to offer better reno-protection.

Experimental approach: C57BLKS-Leprdb/db and control mice were fed a high-protein diet for 9 weeks. After 5 weeks, db/db mice were either exposed to placebo, empagliflozin (SGLT2 inhibitor), monlunabant (CB1 receptor inverse agonist) or a combination of both compounds (same dose) by daily oral gavage for 28 days. Diagnostic parameters for DN were analysed, along with markers of oxidative stress, inflammation and renal fibrosis.

Key results: Both single treatments improved albuminuria and albumin-to-creatinine ratios, but the combination was more effective. Similar results were seen for inflammatory oxidative stress markers. The combination showed additive protective effects on glomerular morphology, podocyte loss and proximal tubular cell injury. Dual treatment significantly reduced tubulointerstitial fibrosis compared to monotherapy and vehicle-treated mice. Transcriptomic analysis identified the STAT3 signalling pathway as a key mediator, with decreased STAT3 phosphorylation observed with both treatments. Key mediators involved included angiopoietin 1 and fibroblast growth factor 20, which modulated the STAT3 pathway via CB1 receptors and SGLT2, respectively.

Conclusions and implications: Taken together, these data strongly suggest that a poly-pharmacological approach combining both SGLT2 inhibitors and CB1 receptor inverse agonism represents a promising therapeutic strategy for managing DN, with better reno-protection than mono-therapies.

Keywords: CB1 receptor; SGLT2; STAT3; diabetic nephropathy; empagliflozin; fibrosis; monlunabant.

PubMed Disclaimer

References

REFERENCES

    1. Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Abbracchio, M. P., Abraham, G., Agoulnik, A., Alexander, W., Al‐Hosaini, K., Bäck, M., Baker, J. G., Barnes, N. M., … Ye, R. D. (2023). The Concise Guide to PHARMACOLOGY 2023/24: G protein‐coupled receptors. British Journal of Pharmacology, 180(Suppl 2), S23–S144. https://doi.org/10.1111/bph.16177
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J., Faccenda, E., Harding, S., Davies, J., Amarosi, L., Anderson, C., Beart, P., Broer, S., Dawson, P., Gyimesi, G., Hagenbuch, B., Hammond, J., Hancox, J., … Verri, T. (2023). The concise guide to PHARMACOLOGY 2023/24: Transporters. British Journal of Pharmacology, 180(Suppl 2), S374–S469. https://doi.org/10.1111/bph.16182
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Annett, S., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Ostrom, R., Papapetropoulos, A., … Wong, S. S. (2023). The Concise Guide to PHARMACOLOGY 2023/24: Enzymes. British Journal of Pharmacology, 180(Suppl 2), S289–S373. https://doi.org/10.1111/bph.16181
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A. A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Davies, J. A., Beuve, A., Brouckaert, P., Bryant, C., Burnett, J. C., Farndale, R. W., Friebe, A., Garthwaite, J., Hobbs, A. J., Jarvis, G. E., … Waldman, S. A. (2023). The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors. British Journal of Pharmacology, 180(Suppl 2), S241–S288. https://doi.org/10.1111/bph.16180
    1. Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175(3), 407–411. https://doi.org/10.1111/bph.14112

MeSH terms

LinkOut - more resources